You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業(01875.HK)核心產品TAB008 III期臨牀試驗達到主要終點
格隆匯 04-21 19:14

格隆匯4月21日丨東曜藥業(01875.HK)公佈,TAB008的隨機III期臨牀試驗最近達到了預設的主要終點。該主要終點比較了TAB008和阿瓦斯汀(Avastin)的療效,是通過評估治療開始後18周(即六個週期,每個週期為三週)內兩組患者的客觀緩解率(ORR)來進行。集團將繼續如期推進TAB008的新藥申請(NDA)。

TAB008是一種抗血管內皮細胞生長因子單克隆抗體(抗VEGFmAb)在研藥物,為貝伐珠單抗(bevacizumab,以阿瓦斯汀的品牌名稱銷售)的在研生物類似藥。阿瓦斯汀一直是最廣泛使用的抗VEGFmAb藥物,自2004年進入市場以來,其療效及安全性得到了廣泛的實踐證明。集團擬使用“樸欣汀(Pusintin)”作為TAB008的品牌名稱。TAB008目前是集團進度最快的在研生物藥,也是公司的核心產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account